FDA warned Ehy Holdings over unupdated drug listings for nicotine patches and creams, calling products misbranded.
What happened
FDA reviewed Ehy Holdings' drug listing information in its electronic Drug Registration and Listing System for ten products, including nicotine transdermal patches and various creams. The company's June 27, 2023 communication showed it was not manufacturing the drugs distributed in the U.S. or imported or offered for import, so its listings did not reference a correct active registered manufacturer and no listing updates were provided. FDA had sent a listing deficiency letter on December 1, 2023, and a data removal email on January 15, 2024.
What FDA found
The firm did not fulfill its drug listing obligations.
section 510(j) of the FD&C Act, 21 U.S.C. 360(j)The listing files identified Ehy Holdings as the manufacturer even though the firm said it was not manufacturing the drugs, so they did not reference a correct active registered manufacturing establishment.
section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i)The listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed and the type of operation at each.
21 CFR 207.49(a)(12)(ii)The firm was registered as a manufacturer even though it stated it was not involved in manufacturing drugs distributed in U.S. commercial distribution or imported or offered for import into the United States.
section 510(j) of the FD&C Act, 21 U.S.C. 360(j)Because the drugs were not properly listed with FDA, they are misbranded drugs.
section 502(o) of the FD&C Act, 21 U.S.C. 352(o)Introducing or delivering such misbranded drugs into interstate commerce is prohibited.
section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, including an explanation of each step to prevent recurrence and copies of related documentation. If corrective actions cannot be completed in that time, the company must state the reason for the delay and when it will complete them.
Who should pay attention
- drug manufacturers and labelers that submit listing files
- distributors of OTC skin creams and nicotine patches
- companies using contract manufacturers for listed drugs
This is a summary. Read the original letter on fda.gov.